GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator
Issued: London, UK
For media and investors only
Download
(PDF, 260.8KB)
Regulatory submission included data from pivotal trials addressing key clinical manifestations of myelofibrosis, namely splenomegaly, constitutional symptoms and anaemia
GSK...
Zur Pressemeldung auf www.gsk.com